Literature DB >> 30968743

A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues.

Lara Pferdehirt1,2,3,4, Alison K Ross1,2,3,4, Jonathan M Brunger5, Farshid Guilak1,2,3,4.   

Abstract

IMPACT STATEMENT: We engineered a synthetic transcription system based on nuclear factor kappa-light-chain-enhancer of activated B cells signaling that can attenuate the effects of the inflammatory cytokine interleukin (IL)-1α in a self-regulating manner. This system responds in a time- and dose-dependent manner to rapidly produce therapeutic levels of IL-1 receptor antagonist (IL-1Ra). The use of lentiviral gene therapy allows this system to be utilized through different transduction methods and in different cell types for a variety of applications. Broadly, this approach may be applicable in developing autoregulated biologic systems for tissue engineering and drug delivery in a range of disease applications.

Entities:  

Keywords:  arthritis; gene therapy; regenerative medicine; stem cells; synthetic biology

Mesh:

Substances:

Year:  2019        PMID: 30968743      PMCID: PMC6533793          DOI: 10.1089/ten.TEA.2019.0027

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  77 in total

1.  Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis.

Authors:  K A Kimmerling; B D Furman; D S Mangiapani; M A Moverman; S M Sinclair; J L Huebner; A Chilkoti; V B Kraus; L A Setton; F Guilak; S A Olson
Journal:  Eur Cell Mater       Date:  2015-01-31       Impact factor: 3.942

Review 2.  The problem of choice: current biologic agents and future prospects in RA.

Authors:  Ernest H Choy; Arthur F Kavanaugh; Simon A Jones
Journal:  Nat Rev Rheumatol       Date:  2013-02-19       Impact factor: 20.543

3.  In vivo gene delivery to synovium by lentiviral vectors.

Authors:  Elvire Gouze; Robert Pawliuk; Carmencita Pilapil; Jean-Noel Gouze; Christina Fleet; Glyn D Palmer; Christopher H Evans; Philippe Leboulch; Steven C Ghivizzani
Journal:  Mol Ther       Date:  2002-04       Impact factor: 11.454

4.  Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.

Authors:  Peter Wehling; Julio Reinecke; Axel W A Baltzer; Markus Granrath; Klaus P Schulitz; Carl Schultz; Rüdiger Krauspe; Theresa W Whiteside; Elaine Elder; Steven C Ghivizzani; Paul D Robbins; Christopher H Evans
Journal:  Hum Gene Ther       Date:  2009-02       Impact factor: 5.695

5.  Application of inflammation-responsive promoter for an in vitro arthritis model.

Authors:  P Sivaramakrishna Rachakonda; Muhammad Farooq Rai; Michael F G Schmidt
Journal:  Arthritis Rheum       Date:  2008-07

6.  Enhanced integrative repair of the porcine meniscus in vitro by inhibition of interleukin-1 or tumor necrosis factor alpha.

Authors:  Amy L McNulty; Franklin T Moutos; J Brice Weinberg; Farshid Guilak
Journal:  Arthritis Rheum       Date:  2007-09

7.  Reprogramming of murine and human somatic cells using a single polycistronic vector.

Authors:  Bryce W Carey; Styliani Markoulaki; Jacob Hanna; Kris Saha; Qing Gao; Maisam Mitalipova; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-24       Impact factor: 11.205

8.  An engineered epigenetic transgene switch in mammalian cells.

Authors:  Beat P Kramer; Alessandro Usseglio Viretta; Marie Daoud-El-Baba; Dominique Aubel; Wilfried Weber; Martin Fussenegger
Journal:  Nat Biotechnol       Date:  2004-06-06       Impact factor: 54.908

9.  Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways.

Authors:  N Wehling; G D Palmer; C Pilapil; F Liu; J W Wells; P E Müller; C H Evans; R M Porter
Journal:  Arthritis Rheum       Date:  2009-03

Review 10.  Autoimmune diseases induced by TNF-targeted therapies.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Maria-Jose Soto; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-10       Impact factor: 4.098

View more
  9 in total

Review 1.  The role of macrophages in osteoarthritis and cartilage repair.

Authors:  C-L Wu; N S Harasymowicz; M A Klimak; K H Collins; F Guilak
Journal:  Osteoarthritis Cartilage       Date:  2020-01-08       Impact factor: 6.576

Review 2.  Engineering Closed-Loop, Autoregulatory Gene Circuits for Osteoarthritis Cell-Based Therapies.

Authors:  Rhima M Coleman
Journal:  Curr Rheumatol Rep       Date:  2022-04-11       Impact factor: 4.592

3.  In vitro analysis of genome-engineered muscle-derived stem cells for autoregulated anti-inflammatory and antifibrotic activity.

Authors:  Lara Pferdehirt; Ping Guo; Aiping Lu; Mathew Huard; Farshid Guilak; Johnny Huard
Journal:  J Orthop Res       Date:  2022-03-16       Impact factor: 3.102

4.  Synthetic gene circuits for preventing disruption of the circadian clock due to interleukin-1-induced inflammation.

Authors:  Lara Pferdehirt; Anna R Damato; Michal Dudek; Qing-Jun Meng; Erik D Herzog; Farshid Guilak
Journal:  Sci Adv       Date:  2022-05-25       Impact factor: 14.957

Review 5.  Immunoengineering the next generation of arthritis therapies.

Authors:  Molly Klimak; Robert J Nims; Lara Pferdehirt; Kelsey H Collins; Natalia S Harasymowicz; Sara J Oswald; Lori A Setton; Farshid Guilak
Journal:  Acta Biomater       Date:  2021-04-03       Impact factor: 8.947

6.  Transient receptor potential vanilloid 4 as a regulator of induced pluripotent stem cell chondrogenesis.

Authors:  Vincent P Willard; Holly A Leddy; Daniel Palmer; Chia-Lung Wu; Wolfgang Liedtke; Farshid Guilak
Journal:  Stem Cells       Date:  2021-08-24       Impact factor: 6.277

7.  A synthetic mechanogenetic gene circuit for autonomous drug delivery in engineered tissues.

Authors:  Robert J Nims; Lara Pferdehirt; Noelani B Ho; Alireza Savadipour; Jeremiah Lorentz; Sima Sohi; Jordan Kassab; Alison K Ross; Christopher J O'Conor; Wolfgang B Liedtke; Bo Zhang; Amy L McNulty; Farshid Guilak
Journal:  Sci Adv       Date:  2021-01-27       Impact factor: 14.136

8.  A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery.

Authors:  Yun-Rak Choi; Kelsey H Collins; Luke E Springer; Lara Pferdehirt; Alison K Ross; Chia-Lung Wu; Franklin T Moutos; Natalia S Harasymowicz; Jonathan M Brunger; Christine T N Pham; Farshid Guilak
Journal:  Sci Adv       Date:  2021-09-01       Impact factor: 14.136

9.  A novel long noncoding RNA, TMEM92-AS1, promotes gastric cancer progression by binding to YBX1 to mediate CCL5.

Authors:  Shubin Song; Xuezhi He; Jing Wang; Hongtao Song; Yimin Wang; Yansong Liu; Zhengbo Zhou; Zhiyong Yu; Dengshun Miao; Yingwei Xue
Journal:  Mol Oncol       Date:  2021-01-12       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.